emapalumab

Home
Ligands
emapalumab

GtoPdb Ligand ID: 9295

Synonyms: emapalumab-lzsg | Gamifant® | NI-0501 | NI0501

emapalumab is an approved drug (FDA (2018))

Comment: Emapalumab (NI-0501) is a fully human monoclonal antibody that targets interferon gamma (IFNγ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2006109191, and in which NI-0501 is confirmed as an exemplary antibody [2].

References
1. FDA. FDA approves emapalumab for hemophagocytic lymphohistiocytosis. Accessed on 21/11/2018. Modified on 21/11/2018. https://www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626280.htm?utm_campaign=Oncology%2011%2F20%2F2018%20emapalumab%20%28GAMIFANT&utm_medium=email&utm_source=Eloqua&elqTrackId=87dd737d161843d8a913014df8c207b1&elq=e82c83f7f52f4e0aad9b0d385665ebb3&elqaid=5965&elqat=1&elqCampaignId=4818
2. Ferlin W, Fischer N, Elson G, Leger O. (2006) Human anti-interferon gamma antibodies and methods of use thereof. Patent number: WO2006109191. Assignee: Novimmune S.A.. Priority date: 27/01/2005. Publication date: 19/10/2006.
3. Pachlopnik Schmid J, Ho CH, Chrétien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, Ferlin W, Geissmann F, Fischer A, de Saint Basile G. (2009) Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med, 1 (2): 112-24. [PMID:20049711]

References

1. FDA.
FDA approves emapalumab for hemophagocytic lymphohistiocytosis.
Accessed on 21/11/2018. Modified on 21/11/2018. https://www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626280.htm?utm_campaign=Oncology%2011%2F20%2F2018%20emapalumab%20%28GAMIFANT&utm_medium=email&utm_source=Eloqua&elqTrackId=87dd737d161843d8a913014df8c207b1&elq=e82c83f7f52f4e0aad9b0d385665ebb3&elqaid=5965&elqat=1&elqCampaignId=4818

2. Ferlin W, Fischer N, Elson G, Leger O. (2006)
Human anti-interferon gamma antibodies and methods of use thereof.
Patent number: WO2006109191. Assignee: Novimmune S.A.. Priority date: 27/01/2005. Publication date: 19/10/2006.

3. Pachlopnik Schmid J, Ho CH, Chrétien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, Ferlin W, Geissmann F, Fischer A, de Saint Basile G. (2009)
Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice.
EMBO Mol Med, 1 (2): 112-24. [PMID:20049711]